Prescription Drug Prices Drop to 60-Year Low

Across multiple reports, prescription drug prices in the United States fell by about 3.1% from a year earlier and 0.8% in the latest month, marking the steepest decline in over six decades though observers caution that a lower CPI does not reflect the exact costs paid by individual patients. The White House credits its Most Favored Nation framework and direct-to-consumer discounts via TrumpRx, along with broader policy actions, for narrowing the gap between U.S. prices and those in other developed countries. Analysts note that price declines arise from a mix of factors, including generic competition, biosimilar entry, and pharmacy-benefit manager reforms, with experts warning that MFN-driven effects may not be durable or evenly distributed. There is ongoing debate about what the data actually measure, since list prices, net prices after rebates, and out-of-pocket costs at the pharmacy can diverge significantly. Despite reductions, the persistent global price gap means Americans may still pay more for branded medicines than peers in comparable countries. Experts emphasize the need for greater price transparency and recognition of how middlemen and insurance design influence what patients ultimately pay, regardless of headline declines.